(Q33933381)

30 July 2017

Insulin analogs with improved pharmacokinetic profiles (English)

1 reference

30 July 2017

1 reference

1 reference

Brange J

1

1 reference

PubMed ID

10837704

30 July 2017

Vølund A

series ordinal

2

1 reference

PubMed ID

10837704

30 July 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

Advanced Drug Delivery Reviews

30 July 2017

1 reference

30 July 2017

35

1 reference

30 July 2017

2-3

1 reference

30 July 2017

307-335

1 reference

Expression in Escherichia coli of chemically synthesized genes for human insulin

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessment using a glucose clamp technique

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Time-action characteristics of regular and NPH insulin in insulin-treated diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Rat Insulin Genes: Construction of Plasmids Containing the Coding Sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Chemical, physical, and biologic properties of biosynthetic human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Secretion and processing of insulin precursors in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Monomeric insulins obtained by protein engineering and their medical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Continuous subcutaneous insulin infusion: Comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Importance of Timing of Preprandial Subcutaneous Insulin Administration in the Management of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Electrophoresis of [35S] Sulphated Insulin. Immunological and Biological Properties of the Isolated Electrophoretic Components

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Structure of Rhombohedral 2 Zinc Insulin Crystals

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Insulin treatment: a decade of change

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Monomeric insulins and their experimental and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

In vitro and in vivo potency of insulin analogues designed for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Hypoglycemic Activity and Immunological Half-life of Porcine Insulin and Proinsulin in Baboons and Swine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Role of B13 Glu in insulin assembly

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

The cobalt(III)-insulin hexamer is a prolonged-acting insulin prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Mutations at the dimer, hexamer, and receptor-binding surfaces of insulin independently affect insulin-insulin and insulin-receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

The structure of 2Zn pig insulin crystals at 1.5 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Altering the association properties of insulin by amino acid replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Changes in secondary structure follow the dissociation of human insulin hexamers: a circular dichroism study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein-ligand complex

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Assembly and dissociation of human insulin and LysB28ProB29-insulin hexamers: a comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Sequence-specific 1H-NMR assignments for the aromatic region of several biologically active, monomeric insulins including native human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Heteronuclear 2D NMR studies of an engineered insulin monomer: assignment and characterization of the receptor-binding surface by selective 2H and 13C labeling with application to protein design

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro --> Asp insulin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Crystal structure of a prolonged-acting insulin with albumin-binding properties

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Toward understanding insulin fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Stability of insulin lispro in insulin infusion systems.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

The new era of biotech insulin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Insulin Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Action profile of the rapid acting insulin analogue: human insulin B28Asp

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties: Evidence From Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9GluB27, AspB10, AspB28) in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

[Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Variation in125i-insulin absorption and blood glucose concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

1 reference

7 January 2021

Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Meal composition is a determinant of lispro-induced hypoglycemia in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Optimal time of administration of insulin lispro. Importance of meal composition

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Are presently available insulin analogues clinically beneficial?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Benefits of lispro insulin: control of postprandial glucose levels is within reach

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Lispro analog for treatment of generalized allergy to human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Severe insulin resistance treated with insulin lispro

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Mixing insulin lispro and ultralente insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Quantitative aspects of subcutaneous insulin absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

The absorption of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900079-9

7 January 2021

10.1016/S0169-409X(98)00079-9

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10837704